🏢 官网IRVEEVCodex · 实盘不做把握 5/10不做原因:证据不足
北京时间·🕒 发布 19:03:00·⟳ 抓取 19:12:12·⚡ 决策 08-25 19:15:57 +3m45s·63.0 天前
Veeva宣布Regeneron全球采用Vault CRM，强化生命科学CRM客户迁移叙事
事件方向正面但缺少合同金额、ARR、收入确认节奏和指引变化，且属于Veeva Vault CRM持续大客户迁移叙事中的又一例；无法形成可执行正期望。
📄 原文VEEV↗ 原文
Veeva Vault CRM Selected by Regeneron
Leading biopharma company selects agentic CRM for life sciences to generate Commercial Evidence PLEASANTON, Calif. , Au…
不做 Veeva Systems（VEEV.US）
正面但无合同金额、ARR或指引变化，且Vault CRM大型客户采用已是连续明牌叙事；短线edge不足。
不做 Regeneron Pharmaceuticals（REGN.US）
Regeneron只是CRM采购方，当前新闻没有形成公司级收入或利润增量。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Veeva一手IR新闻稿确认Regeneron全球采用Vault CRM，这强化了Veeva在生命科学CRM中的客户迁移势能；但新闻稿没有披露合同金额、ARR、席位、上线时间或利润影响，无法完成新增收入和市值占比量级核查。Regeneron作为采购方不构成交易受益标的。综合新鲜度、预期差和先例质量，本次不下新仓。
消息传播链
- Veeva一手IR新闻稿宣布Regeneron全球采用Vault CRM，未披露金额或指引变化。
- PRNewswire同步发布原始通稿，内容与IR稿一致，未增加财务量级信息。
关键理由
- Regeneron全球采用Vault CRM为Veeva增加大型药企客户背书，方向上利好产品竞争力。
- 量级无法核查：Veeva已有较大收入基数，本次未披露合同金额或ARR，无法估算新增收入、利润或市值占比。
- 同类Vault CRM客户采用此前已多次披露，本次更像持续执行而非足以单独重估的突破。
主要风险
- 未披露合同金额和实施节奏，客户承诺不等同于短期收入确认。
- 若盘前或开盘显著跳涨，无金额软催化可能缺少基本面承接。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-06-04 · 影响 weakens
Veeva此前已公开讨论Vault CRM大型药企胜率和剩余决策，本次客户赢单的预期差被部分削弱。
检索:Veeva Vault CRM customer wins already expected top 20 biopharma remaining decisions 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-25 · 影响 weakens
公司通稿未披露合同金额、ARR、上线时间或指引上修，无法完成收入和市值量级核查。
检索:Veeva Vault CRM Regeneron contract amount ARR guidance 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例使本次从方向利好降为不交易：确认叙事延续，但不足以支持ENTER、仓位或tp/sl。
方向:同类事件方向偏正面，主要证明Vault CRM客户迁移动能仍在。
涨幅量级:可得先例均为无金额客户采用新闻，缺少高相似且可量化合同金额或指引变化样本，不能用于设定涨幅目标。
形态:无金额SaaS客户新闻存在高开后缺乏基本面量化承接的风险；样本不足以证明稳定短线胜率。
历史先例(按相似度)
- 相似度 7/10 VEEV 2026-08-11 Veeva宣布Eli Lilly全球采用Vault CRM，未披露合同额或ARR。 原文 ↗
事件后 +1日 +0.8% · +2日 +2.9% · +3日 +7.7% · +4日 +3.9% · +5日 +1.6%
⚠锚前1-2日已异动7.8%>锚定日0.8%·未核对目标相位 — 该行涨幅别用来定止盈止损
相似度依据:同一公司、同一Vault CRM全球客户采用机制，客户为Eli Lilly且同样未披露金额。
经验:大型客户背书能强化产品叙事，但无金额客户新闻通常只能确认方向，难以支撑幅度。 - 相似度 6/10 VEEV 2026-05-27 Veeva宣布Merck KGaA全球采用Vault CRM。 原文 ↗
事件后 +1日 -0.0% · +2日 +3.7% · +3日 +10.0% · +4日 +19.0% · +5日 +15.4%
⚠未核对目标相位 — 该行涨幅别用来定止盈止损
相似度依据:同一产品线全球采用新闻，客户为Merck KGaA，机制相同但客户和事件阶段不同。
经验:连续客户采用会降低单条新闻意外性，需要金额或指引变化才能显著提高交易把握。 - 相似度 6/10 VEEV 2026-01-07 Novo Nordisk International Operations承诺采用Veeva Vault CRM。 原文 ↗
事件后 +1日 +0.6% · +2日 +1.4% · +3日 +0.9% · +4日 -2.0% · +5日 -3.9%
⚠锚前1-2日已异动8.4%>锚定日0.6%·未核对目标相位 — 该行涨幅别用来定止盈止损
相似度依据:同一公司同一产品线、同为大型药企采用，但为Novo Nordisk International Operations业务单元而非Regeneron全球采用。
经验:客户名单扩张支持中期竞争力，但无金额新闻的短线胜率和幅度需谨慎。
原文全文
展开原文 · 3,066 字
Leading biopharma company selects agentic CRM for life sciences
to generate Commercial Evidence
PLEASANTON, Calif.
,
Aug. 25, 2026
/PRNewswire/ --
Veeva Systems
(NYSE: VEEV) today announced that Regeneron Pharmaceuticals has committed to
Veeva Vault CRM
globally. With Vault CRM, Regeneron plans to generate Commercial Evidence from AI-powered field engagement, uncovering hidden barriers to treatment adoption and ensuring their medicines can reach eligible patients in need.
"We are pleased to expand our strategic partnership with Veeva by moving to Vault CRM, which will give our commercial teams a more connected platform and help them get faster access to the information they need for efficient decision-making," said Ryan Steinberger, executive vice president and chief digital and technology officer at Regeneron.
"Regeneron uses the power of science to invent, develop, and commercialize life-transforming medicines for people with serious diseases," said Matt Farrell, president, commercial strategy at Veeva. "We are honored to extend our strategic partnership with Regeneron to include Veeva Vault CRM as they continue to deliver important new medicines to people in need."
Vault CRM is part of the Vault CRM Suite of applications that provide the technology foundation for commercial execution. With the Agentic Call Report in Vault CRM, every field interaction becomes a source of
Commercial Evidence
, capturing insights previously lost to dropdowns and compliance concerns.
About Veeva Systems
Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a
Public Benefit Corporation
, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit
veeva.com
.
Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended April 30, 2026, which you can find
here
(a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at
sec.gov
.
Contact:
Maria Scurry
Veeva Systems
maria.scurry@veeva.com
Meera Lakhani-Patel
Veeva Systems, Europe
meera.lakhani-patel@veeva.com
View original content to download multimedia:
https://www.prnewswire.com/news-releases/veeva-vault-crm-selected-by-regeneron-302858870.html
SOURCE Veeva Systems
to generate Commercial Evidence
PLEASANTON, Calif.
,
Aug. 25, 2026
/PRNewswire/ --
Veeva Systems
(NYSE: VEEV) today announced that Regeneron Pharmaceuticals has committed to
Veeva Vault CRM
globally. With Vault CRM, Regeneron plans to generate Commercial Evidence from AI-powered field engagement, uncovering hidden barriers to treatment adoption and ensuring their medicines can reach eligible patients in need.
"We are pleased to expand our strategic partnership with Veeva by moving to Vault CRM, which will give our commercial teams a more connected platform and help them get faster access to the information they need for efficient decision-making," said Ryan Steinberger, executive vice president and chief digital and technology officer at Regeneron.
"Regeneron uses the power of science to invent, develop, and commercialize life-transforming medicines for people with serious diseases," said Matt Farrell, president, commercial strategy at Veeva. "We are honored to extend our strategic partnership with Regeneron to include Veeva Vault CRM as they continue to deliver important new medicines to people in need."
Vault CRM is part of the Vault CRM Suite of applications that provide the technology foundation for commercial execution. With the Agentic Call Report in Vault CRM, every field interaction becomes a source of
Commercial Evidence
, capturing insights previously lost to dropdowns and compliance concerns.
About Veeva Systems
Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a
Public Benefit Corporation
, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit
veeva.com
.
Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended April 30, 2026, which you can find
here
(a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at
sec.gov
.
Contact:
Maria Scurry
Veeva Systems
maria.scurry@veeva.com
Meera Lakhani-Patel
Veeva Systems, Europe
meera.lakhani-patel@veeva.com
View original content to download multimedia:
https://www.prnewswire.com/news-releases/veeva-vault-crm-selected-by-regeneron-302858870.html
SOURCE Veeva Systems
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。